Orbimed Advisors Llc - May 26, 2022 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
10%+ Owner
Signature
/s/ Carl Gordon, Member of OrbiMed Advisors LLC
Stock symbol
PMVP
Transactions as of
May 26, 2022
Transactions value $
-$418,210
Form type
4
Date filed
5/31/2022, 04:36 PM
Previous filing
May 20, 2022
Next filing
Jun 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMVP Common Stock Sale -$418K -26.3K -23.02% $15.93 87.8K May 26, 2022 See Footnotes F1, F2, F3, F5
holding PMVP Common Stock 6.48M May 26, 2022 See Footnotes F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the sale of shares of the Issuer's common stock ("Shares"), which was effected after market close on May 26, 2022.
F2 These Shares were sold in multiple transactions at prices ranging from $15.55 to $16.09. The price reported reflects the weighted average sale price. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote.
F3 The Shares are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
F4 The Shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.4.
F5 This report on Form 4 is jointly filed by OrbiMed Advisors, GP V and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.